What Is the First-Line Treatment for Lichen Simplex Chronicus?

Lichen simplex chronicus (LSC) is a chronic pruritic dermatosis sustained by the itch-scratch cycle. First-line management targets both the inflammatory component at the affected skin and the behavioural drivers of repeated scratching, with response evaluated at a structured follow-up point.

Treatment approach (partial)

Management centres on targeted topical anti-inflammatory therapy applied to thicker affected plaques during flares, combined with patient counselling on trigger avoidance and behavioural strategies to interrupt the scratch cycle. Where initial topical therapy is insufficient or where anatomical site requires an alternative, additional topical options are available.

Full agent selection, sequencing, escalation criteria, and long-term management options are in the complete protocol ↓

✓

Treatment goal: Reduction of pruritus and inflammation at the affected skin, with response assessed at follow-up around week 3.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-025-00979-z

The first-line treatment for LSC is topical corticosteroids (TCS) applied on thicker plaques during flares to reduce inflammation and pruritus.
Patients should be counseled to avoid known triggers such as heat, stress, and skin irritants, and to wear loose, breathable cotton-blend clothing.
Behavioral strategies, including stress management and habit-reversal therapy, are essential for reducing scratching behavior.
These are typically applied in small amounts twice daily for 2–3 weeks, with a follow-up visit around week 3 to assess response and guide tapering.

View source ↗